Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.62 |
| ▸ | CPT2 | P23786 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.34 |
| ▸ | FDPS | P14324 | 2/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.32 |
| ▸ | ARG2 | P78540 | 1/20 | 0.32 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18760169 | 0.91 | FFAR1 (0.54) | FFAR1CPT2TDP1SMPD1FDPS | |
| SCHEMBL6667493 | 0.91 | FFAR1 (0.52) | FFAR1CPT2TDP1KDM4EARG1 | |
| SCHEMBL5215247 | 0.86 | FFAR1 (0.46) | FFAR1CPT2TDP1KDM4E | |
| SCHEMBL16280996 | 0.81 | KDM4E (0.42) | FFAR1CPT2TDP1KDM4EFDPS | |
| SCHEMBL1578074 | 0.80 | LMNA (0.43) | FFAR1CPT2TDP1KDM4ESMPD1 | |
| SCHEMBL21626032 | 0.80 | FFAR1 (0.39) | FFAR1CPT2TDP1KDM4E | |
| SCHEMBL8037883 | 0.77 | FFAR1 (1.00) | FFAR1CPT2TDP1KDM4EACLY | |
| SCHEMBL5523390 | 0.77 | FFAR1 (1.00) | FFAR1CPT2TDP1KDM4EACLY | |
| SCHEMBL1834211 | 0.77 | FFAR1 (1.00) | FFAR1CPT2TDP1KDM4EACLY | |
| SCHEMBL1832938 | 0.77 | FFAR1 (1.00) | FFAR1CPT2TDP1KDM4EACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0081930-B1 | LONG-CHAIN ALPHA, OMEGA-DICARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Epis S.A. (CH) | 1986-07-30 | — | — | EP | claimed |
| EP-0081930-A1 | Long-chain alpha, omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them | Epis S.A. (CH) | 1983-06-22 | — | — | EP | claimed |
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY (US) | 2007-08-30 | — | — | US | disclosed |
| US-20050026979-A1 | Methods for treating inflammation and inflammation-associated diseases with a statin and ether | GHAZZI MAHA (US) | 2005-02-03 | — | — | US | disclosed |
| US-20050004196-A1 | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| US-20040167229-A1 | Method of lowering CRP and reducing systemic inflammation | BAKKER-ARKEMA REBECCA (US) | 2004-08-26 | — | — | US | disclosed |
| US-20040048910-A1 | Dialkyl ether di-substituted with formyl, carboxy acid, ester and/or tetrazole, which are on tertiary carbon atoms, e.g., 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid; lupus, connective tissue disease, sepsis, joint pain | WARNER-LAMBERT COMPANY | 2004-03-11 | — | — | US | disclosed |
| US-4689344-A | ANTICHOLESTEROL AGENTS | EPIS S.A. (CH) | 1987-08-25 | — | — | US | disclosed |
| US-4634795-A | TREATMENT OF OBESITY, HYPERLIPIDEMIA, AND MATURITY-ONSET DIABETES | EPIS S.A. (CH) | 1987-01-06 | — | — | US | disclosed |
| EP-0081930-B1 | LONG-CHAIN ALPHA, OMEGA-DICARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Epis S.A. (CH) | 1986-07-30 | — | — | EP | disclosed |
| EP-0081930-A1 | Long-chain alpha, omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them | Epis S.A. (CH) | 1983-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048910-A1 | Dialkyl ether di-substituted with formyl, carboxy acid, ester and/or tetrazole, which are on tertiary carbon atoms, e.g., 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid; lupus, connective tissue disease, sepsis, joint pain | TLR5, SSB, TLR4 | FFAR1 144/4885CPT2 360/4885TDP1 2229/4885 |
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | SYVN1, MMP13, TNF | FFAR1 1371/4885CPT2 714/4885TDP1 3613/4885 |
| US-20050026979-A1 | Methods for treating inflammation and inflammation-associated diseases with a statin and ether | HMGCR, CXCL8, DHCR7 | FFAR1 265/4885CPT2 434/4885TDP1 3202/4885 |
| US-20050004196-A1 | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such | PTGES2, PTGES, PTGER2 | FFAR1 449/4885CPT2 1268/4885TDP1 4216/4885 |
| US-20040167229-A1 | Method of lowering CRP and reducing systemic inflammation | ALB, TTR, IL6 | FFAR1 96/4885CPT2 2128/4885TDP1 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.